Hints and tips:
...“Pfizer is very good at selling but historically not renowned as having the R&D engine of a Merck or Lilly....
...Merck looks to take the lead The most keenly awaited study at this year’s meeting is a large trial of Merck’s immunotherapy drug, Keytruda, in patients with a common type of lung cancer....
...Gilbert is a founder of B-Lab, which in 2007 began certifying a new type of company called a B Corporation, with a mandate to benefit all stakeholders and a commitment to submit to regular tests of its social...
...A spokesperson for Merck Sharp & Dohme – the name under which the US group operates in Europe – said it is cooperating fully with the CMA’s investigation, and said: MSD is confident that the proceedings...
...With shareholder expectations running high ahead of the event, the data have the potential to prompt sharp movements in share prices — in either direction....
...Such an environment would also hurt other large US healthcare groups that derive a big chunk of their sales from overseas such as Merck & Co and Johnson & Johnson, as well as consumer goods companies like...
...Mergers led the US company to become known as Merck Sharp & Dohme, which prompted a 1950s agreement for it to keep exclusive rights to the Merck name in North America while calling itself MSD everywhere...
...Mergers led the US company to become known as Merck Sharp & Dohme, and this spurred a 1950s agreement for it to keep exclusive rights to the family name in North America while calling itself MSD everywhere...
...“For the world to continue to have new antibiotics, we need investments in basic science and novel incentive models for industry R&D,” he said....
...It drives growth and attracts a wealth of global corporations, investors and charities....
...Merck, the biggest US drugmaker by sales after Pfizer, also beat Wall Street expectations with second-quarter results despite a 1 per cent fall in revenues to $10.9bn....
...A combination of weak US economic data and little indication of progress in Washington sent US equities lower, led by a sharp sell-off in the utilities sector....
...US Airways shares lost 4.6 per cent to $13.99 after the airline said it was set to merge with AMR Corporation, the parent company of American Airlines, in a deal with a combined equity value of $11bn....
...Merck Sharp and Dohme sells its patented diabetes drug Januvia in India for about $24 per month, 80 per cent lower than its global price....
...“The corporation tax rate is a signal in terms of the government having a positive agenda for inward investment,” he said....
...Sage Bionetworks, a Seattle-based non-profit outfit, was spun out of Merck to try to do just this....
...Critics such as Steven Nissen, a cardiologist at the Cleveland Clinic in the US who three years ago helped stoke public and political concern – and a sharp drop in prescriptions – by suggesting that the...
...“It seemed a general and vague statement, and I’d like to see a lot more flesh on the bones....
...“The loss of any pharma industry R&D is a worry....
...It needed marketing clout it could not muster alone – especially if it was to go head-to-head with the bigger Merck. In 1996, it signed a deal to co-develop Lipitor with Pfizer....
...AstraZeneca has agreed development projects with Bristol-Myers Squibb on a diabetes drug and with Merck for a cancer treatment....
...“I’d be looking for synergies on the top line. I don’t want to do a deal just to save costs.”...
...A preventative vaccine for Hepatitis B can prevent liver cancer. Research continues on a possible Hepatitis C vaccine, which could also prevent liver cancer....
...After a rebound in the following session, the shares sol d off towards the end of the week....
...The film had been slate d for release in November 2005....
International Edition